APA (7th ed.) Citation

M, R., JD, P., JE, G., N, R., M, C., JF, P., . . . BC, C. (2026). First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 21(3), 103509. https://doi.org/10.1016/j.jtho.2025.10.016

Chicago Style (17th ed.) Citation

M, Reck, et al. "First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 21, no. 3 (2026): 103509. https://doi.org/10.1016/j.jtho.2025.10.016.

MLA (9th ed.) Citation

M, Reck, et al. "First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 21, no. 3, 2026, p. 103509, https://doi.org/10.1016/j.jtho.2025.10.016.